Urolithin A: The Mitophagy Molecule That Actually Has Clinical Trial Data

Most longevity supplements have mechanistic hypotheses and animal data. Urolithin A is unusual: Timeline Nutrition has published randomized controlled trials in humans showing mitophagy induction, improved muscle endurance, and better mitochondrial function. Here's the complete evidence review.

Most longevity supplements have a pattern: animal data → mechanistic hypothesis → extrapolated human promise → product. Urolithin A breaks this pattern. Timeline Nutrition — the company behind Mitopure, the most studied urolithin A product — has published multiple randomized controlled trials in humans. They have measured mitophagy induction directly, shown improvements in muscle endurance and strength, and demonstrated biomarker changes consistent with improved mitochondrial function. This is unusual in the supplement industry.

Here is the complete evidence review, the mechanism, what the trials actually show, and how to choose between the available urolithin A products.

What Is Urolithin A?

Urolithin A is a metabolite produced when gut bacteria ferment ellagitannins — polyphenols found in pomegranates, walnuts, and some berries. The production is gut-microbiome dependent: only about 40% of people have the right bacterial populations to produce urolithin A from pomegranate consumption alone. The rest get no urolithin A from food regardless of how much pomegranate they eat.

This microbiome dependency explains why direct urolithin A supplementation was developed — bypassing the gut bacteria step entirely to deliver urolithin A directly.

The Mechanism: Mitophagy Induction

Mitophagy is the selective autophagy (cellular self-cleaning) of damaged or dysfunctional mitochondria. Healthy cells continuously produce new mitochondria (mitogenesis) and clear out old, inefficient ones (mitophagy). With aging, mitophagy becomes impaired — damaged mitochondria accumulate, reducing cellular energy production and increasing oxidative stress. Mitochondrial dysfunction is one of the 12 hallmarks of aging identified in the 2023 updated framework.

Urolithin A induces mitophagy via multiple mechanisms. The best characterized: it promotes PINK1-Parkin pathway activation, the dominant selective mitophagy pathway in mammals. It also upregulates general autophagy and activates AMPK. In *C. elegans*, urolithin A extended lifespan by ~45% and improved muscle function in aged worms. In mice, it improved exercise endurance, reduced muscle inflammation, and preserved function during aging.

The Human Clinical Trials

Trial 1: PLOS ONE (2019) — Randomized, double-blind, placebo-controlled trial in 60 adults (40–65 years). Primary endpoint: urolithin A pharmacokinetics and biomarkers. Results: oral urolithin A (500 mg and 1000 mg/day × 4 weeks) was well-tolerated, produced dose-dependent plasma levels, and increased mitophagy-related gene expression in skeletal muscle biopsies. This was the first human evidence that oral urolithin A reaches skeletal muscle and induces mitophagy in humans.

Trial 2: Nature Aging (2022) — Timeline's landmark trial. 88 adults aged 65+ (low muscle fitness at baseline), randomized to Mitopure 500 mg, Mitopure 1000 mg, or placebo for 4 months. Primary endpoint: muscle endurance (handgrip and leg endurance). Results:

• 1000 mg Mitopure: significant improvement in hand grip muscle endurance (sustained handgrip force test, p=0.0069 versus placebo)
• 500 mg: trend toward improvement, not significant
• Both doses: significantly higher plasma acylcarnitine (mitochondrial function marker)
• Both doses: significantly higher NAD+ pathway metabolites
• No significant change in overall muscle strength (1-rep max, 6-minute walk test)

Trial 3: European Journal of Clinical Nutrition (2021) — Bioavailability comparison. Mitopure vs pomegranate juice. Result: Mitopure produced 6× higher plasma urolithin A versus equivalent-dose pomegranate juice. The microbiome dependency is real.

Trial 4 (ongoing, 2024–2026): Multiple trials testing urolithin A in middle-aged adults, including endpoints related to VO2 max, DNA repair, and inflammatory markers. Results expected 2026–2027.

What the Trials Show — and What They Don't

Clear evidence:

• Oral urolithin A reaches skeletal muscle in humans (muscle biopsy confirmation)
• It induces mitophagy-related gene expression in muscle
• At 1000 mg/day × 4 months, it significantly improves muscle endurance in sedentary older adults
• It is well-tolerated with no serious adverse events across all trials

Still uncertain:

• Does it improve strength (not just endurance)? The 2022 trial found no effect on 1-rep max
• Does it benefit younger, already-fit individuals? All published trials used sedentary or low-fitness older adults
• Long-term effects beyond 4 months?
• Cardiovascular endpoints beyond muscle?

Choosing Between Urolithin A Products

Timeline Mitopure is the only urolithin A product with published human clinical trial data. The generic urolithin A supplements that have proliferated in recent years (at much lower prices) have not been tested in humans and may use different urolithin A purity or formulation.

Timeline Mitopure Softgels (500 mg per softgel): The dose used in the positive primary endpoint of the Nature Aging trial was 1000 mg/day. Two softgels per day. The most convenient format for achieving the clinical dose.

Timeline Mitopure Powder (500 mg per sachet): Equivalent dose in powder form, mixes into drinks or food. More economical per serving than softgels.

As an Amazon Associate, Stacking Years earns from qualifying purchases.

Stacking with Other Mitochondrial Interventions

Urolithin A works via mitophagy (clearing old mitochondria). NAD+ precursors (NMN/NR) support the mitochondria that remain by maintaining the redox coenzyme supply. Zone 2 exercise drives mitochondrial biogenesis — creating new mitochondria. These three mechanisms are complementary, not redundant.

The mitochondrial optimization stack: urolithin A (mitophagy) + NMN or NR (NAD+/sirtuin function) + Zone 2 cardio (biogenesis) + resistance training (mitochondrial content in muscle) is the most evidence-informed approach to preserving mitochondrial health with aging.

The Bottom Line

Urolithin A stands out in the supplement landscape for one reason: it has placebo-controlled human trial evidence for muscle-relevant endpoints. The 1000 mg/day dose produced statistically significant improvements in muscle endurance in a 4-month RCT. The mitophagy mechanism is confirmed in human skeletal muscle.

The limitations are real: the evidence is in sedentary older adults, the effect on strength (versus endurance) is not established, and long-term data beyond 4 months is not yet available. But relative to most supplements, the evidence bar is substantially higher, and the cost has come down enough that the risk-benefit calculation is favorable for adults over 40 concerned about muscle aging and mitochondrial function.